BEIJING, July 22, 2024 /PRNewswire/ -- Recently, Gan & Lee Pharmaceuticals(Gan & Lee, Shanghai Stock Exchange: 603087) announced that its independently developed long-acting GLP-1 receptor agonist (GLP-1 RA), GZR18 injection, has achieved positive results in a clinical trial for adults with obesity/overweight in China.
Statement:
1. GZR18 injection is an investigational drug and has not yet been approved in China.
2. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications.
The phase IIb clinical trial (CTR20231695) is a multi-center, randomized, double-blind, placebo-controlled study conducted at 25 clinical trial centers in China, recruiting a total of 340 participants. The participants were overweight (BMI≥24 kg/m2) with at least one weight-related comorbidity or obese (BMI≥28 kg/m2) adults with poorly controlled diet and exercise. They were randomized to receive bi-weekly (Q2W) doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly (QW) dose of 24 mg GZR18 injection or placebo for 30 weeks (including a dose escalation period). The primary efficacy endpoint of the study was the percent change in body weight from baseline after 30 weeks of treatment. The study assessed changes from baseline in average weight, waist circumference, waist-to-hip ratio, body mass index (BMI), glycemic parameters, and the safety and tolerability of the drug.
After 30 weeks of treatment, compared to the placebo group, participants receiving different doses and frequencies of GZR18 injection (12 mg, 18 mg, 24 mg, and 48 mg Q2W; 24 mg QW) had a significant reduction in the percent change in body weight from baseline. The mean percent changes in body weight from baseline was -11.15% (12 mg group, Q2W), -13.22% (18 mg group, Q2W), -14.25% (24 mg group, Q2W), -17.29% (48 mg group, Q2W), and -17.78% (24 mg group, QW), all more effective than the placebo group (reduced by 0.99%). There was no significant difference in mean percent change in body weight between the 48 mg Q2W group and the 24 mg QW group (one-sided test, P > 0.025).
In this study, the bi-weekly GZR18 injections were generally safe and well tolerated, consistent with the known safety signals of GLP-1 receptor agonists. The most common adverse events were gastrointestinal reactions, most of which were mild to moderate in severity, comparable to other GLP-1 RAs.
The comprehensive results of this phase IIb study are planned to be announced later this year and will be published in a peer-reviewed journal.
About Gan & Lee
Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilinâ„¢), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilinâ„¢25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).
In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first among domestic companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets.
In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.
Further Information:
BPRD@ganlee.com (Media)
BD@ganlee.com (Business Development)
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
HONG KONG, Nov. 23, 2024 /PRNewswire/ -- The presentation ceremony for the Hong Kong ICT Awards 2024 was held in the evening of November 22 with MTR Corporation / The Hong Kong University of Science and Technology being presented the Award of the Year from the Financial Secretary, Mr Paul Chan. MTR Corporation / The Hong Kong University of Science and Technology is also the winner of the Smart Mobility Grand Award, surpassing seven other category winners with its winning entry "Public transport ridership simulation and railway planning – MTR to Keep Cities Moving".
Mr Chan said, "The ICT Awards put a deserved spotlight on the remarkable talent, creativity and dedication of the people seeking to harness technology to reinvent products and services, to improve efficiency, to offer better care to the needy, and ultimately to make our lives and the world better."
Noting this year's Hong Kong ICT Awards has introduced the "Best Use of AI" Award, Mr Chan said the Hong Kong Special Administrative Region Government believes in the vast potential of artificial intelligence (AI) which is a sweeping force in boosting productivity and enhancing the competitiveness of economy. And the Government has been working on multiple fronts to make it thrive, through supporting research and development, nurturing startups, fostering cross-boundary and cross industry collaboration, attracting strategic enterprises, and building the related infrastructure, including a supercomputing centre.
The Hong Kong ICT Awards aims to recognise and promote outstanding local Information and Communications Technology (ICT) innovations and applications. It has been well-received as an annual flagship event of the local industry since its debut in 2006. In addition to encouraging and recognising local innovations, the Awards also serves as a springboard to help the winners and their products enter the Mainland and overseas markets.
Organised by the Digital Policy Office and supported by the collaborative efforts of eight Leading Organisers, the Steering Committee, the Standards Assurance Sub-committee, the Grand Judging Panel, the Marketing and Promotion Sub-committee, judges, supporting organisations and industry associations, this year's competition concluded successfully. The Chairman of the Grand Judging Panel, the President of Lingnan University, Professor Joe Qin, congratulated the awardees and praised their innovative solutions for bringing unlimited possibilities to life and benefiting society as a whole.
Professor Qin said, "In the era of artificial intelligence, the newly introduced 'Best Use of AI Award' inspires further innovative applications, ensuring that information and communications technology remains in tune with the times and sustainable development." He firmly believes that education, technology, and talent are closely interconnected and encourages everyone to experiment and to contribute to shaping a brighter future together.
The Secretary for Innovation, Technology and Industry, Professor Sun Dong, presented trophies to the eight winners of Grand Awards to commend their outstanding performance. The awardees are:
Award category
(Leading Organiser)
Grand Award winner
(winning entry)
Digital Entertainment Grand Award
(Hong Kong Digital Entertainment Association)
AITHER ENTERTAINMENT LIMITED
(Apeiron)
FinTech Grand Award
(Institute of Financial Technologists of Asia)
Evident Limited
(EVIDENT)
ICT Startup Grand Award
(Hong Kong Wireless Technology Industry Association)
Neurodyssey Association Limited
(Neurofeedback AI-Based Mapping Expert System ("NAMES"))
Smart Business Grand Award
(Hong Kong Computer Society)
Transcendence Company Limited
(C-SMART Site Safety System)
Smart Living Grand Award
(Hong Kong Information Technology Federation)
Logital Co. Limited
(Savoir by EasyHear)
Smart Mobility Grand Award
(GS1 Hong Kong)
MTR Corporation / The Hong Kong University of Science and Technology
(Public transport ridership simulation and railway planning – MTR to Keep Cities Moving)
Smart People Grand Award
(The Hong Kong Council of Social Service)
Hong Kong Young Women's Christian Association / St. James' Settlement / Hong Kong Lutheran Social Service, LC-HKS / Hong Chi Association
(The Hong Kong Jockey Club e-Platform to Achieve Smart Service for On-site Pre-school Rehabilitation Services (e-PASS OPRS))
Student Innovation Grand Award
(Hong Kong Education City)
St. Paul's Co-educational College (Ms Clarisse POON)
(Medisafe)
Besides, the winning entry "Medisafe" has fully demonstrated effective application of computational thinking for problem-solving, as well as students' great potential in the field of ICT. As such, the Grand Judging Panel unanimously recommended Ms Clarisse Poon of St. Paul's Co-educational College to receive the "Special Recognition Award" as an encouragement and commendation for her remarkable performance. The award was presented by Professor Qin to Ms Poon.
Detailed information of the winners and the event are available on the website of the Hong Kong ICT Awards (www.hkictawards.hk).
Download captioned photos and more:
https://drive.google.com/drive/folders/1wwBCs377rOfqsk70gPYocvampRb-lhcf?usp=sharing
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
